167 related articles for article (PubMed ID: 35476248)
1. Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis.
Bellinato F; Gisondi P; Mason E; Ricci P; Maurelli M; Girolomoni G
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1303-1311. PubMed ID: 35476248
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
[TBL] [Abstract][Full Text] [Related]
3. Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience.
Maurelli M; Girolomoni G; Gisondi P
J Dermatolog Treat; 2023 Dec; 34(1):2218504. PubMed ID: 37272368
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
[TBL] [Abstract][Full Text] [Related]
5. Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis.
Gisondi P; Geat D; Armeni P; Bellinato F; Maurelli M; Girolomoni G
Expert Opin Biol Ther; 2022 Dec; 22(12):1579-1584. PubMed ID: 35466843
[TBL] [Abstract][Full Text] [Related]
6. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
[TBL] [Abstract][Full Text] [Related]
8. A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study.
Barberio B; Cingolani L; Canova C; Barbieri G; Sablich R; Urbano MT; Bertani L; Costa F; Bodini G; Demarzo MG; Ferronato A; Buda A; Melatti P; Massimi D; Savarino EV; Zingone F
Therap Adv Gastroenterol; 2021; 14():17562848211031420. PubMed ID: 34349836
[TBL] [Abstract][Full Text] [Related]
9. A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator.
Giunta A; Zangrilli A; Bavetta M; Manfreda V; Pensa C; Bianchi L
Curr Med Res Opin; 2021 Jul; 37(7):1099-1102. PubMed ID: 34011212
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
Lu X; Hu R; Peng L; Liu M; Sun Z
Front Immunol; 2021; 12():638444. PubMed ID: 33889152
[TBL] [Abstract][Full Text] [Related]
11. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
[TBL] [Abstract][Full Text] [Related]
12. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
Zhou X; Chen Z; Bi X
Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
[TBL] [Abstract][Full Text] [Related]
13. Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study.
Phan DB; Jourdain H; González-Quesada A; Zureik M; Rivera-Díaz R; Sahuquillo-Torralba A; Descalzo-Gallego MA; Lunt M; Garcia-Doval I; Sbidian E; Warren RB; Yiu ZZN
BMJ Open; 2023 Jul; 13(7):e075197. PubMed ID: 37451726
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
Cingolani L; Barberio B; Zingone F; Ferronato A; Bertani L; Costa F; Bodini G; Demarzo MG; Melatti P; Gubbiotti A; Massimi D; Casadei C; D'Incà R; Savarino EV
Sci Rep; 2021 May; 11(1):10368. PubMed ID: 33990652
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study.
Megna M; Fornaro L; Potestio L; Luciano MA; Nocerino M; Delfino M; Guarino M; Fabbrocini G; Camela E
Psoriasis (Auckl); 2022; 12():199-204. PubMed ID: 35844291
[TBL] [Abstract][Full Text] [Related]
16. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
Tursi A; Mocci G; Cuomo A; Ferronato A; Elisei W; Picchio M; Maconi G; Scaldaferri F; Papa A; ; Allegretta L; Aragona G; Bianco MA; Colucci R; Della Valle N; Faggiani R; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Pica R; Pranzo G; Rodino' S; Sacco R; Sebkova L; Scarcelli A; Serio M; Napolitano D; Pugliese D; Schiavoni E; Turchini L; Armuzzi A; Zampaletta C
J Gastrointestin Liver Dis; 2022 Dec; 31(4):411-416. PubMed ID: 36535057
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
20. A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
Lukas M; Kolar M; Reissigova J; Duricova D; Machkova N; Hruba V; Lukas M; Vasatko M; Jirsa J; Pudilova K; Malickova K
Scand J Gastroenterol; 2022 Jul; 57(7):814-824. PubMed ID: 35234552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]